Zomedica Corp. Cash Flow Statement
ZOMDF|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Zomedica Corp. used $18M in operating cash flow and negative free cash flow of $18M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$81.9M | -$47.0M | -$34.5M | -$17.0M | -$18.4M | -$16.9M |
| Depreciation & Amortization | $2.1M | $1.5M | $830.0K | $426.0K | $265.0K | $305.9K |
| Operating Cash Flow | -$17.6M | -$23.6M | -$16.0M | -$11.7M | -$14.3M | -$16.2M |
| Capital Expenditures | $567.0K | $5.2M | $11.3M | $787.0K | $147.0K | $14.8K |
| Free Cash Flow | -$18.2M | -$28.8M | -$27.3M | -$12.5M | -$14.4M | -$16.3M |
| FCF Margin | -56.9% | -105.7% | -108.5% | -65.8% | -349.0% | - |